Literature DB >> 34272440

Clinical characteristics of optic neuritis phenotypes in a 3-year follow-up Chinese cohort.

Chaoyi Feng1, Qian Chen1, Guixian Zhao2, Zhenxin Li2, Weimin Chen3, Yan Sha4, Xinghuai Sun1,5, Min Wang6,7, Guohong Tian8,9.   

Abstract

To evaluate the clinical characteristics of optic neuritis (ON) with different phenotypes. This prospective study recruited patients with new-onset ON between January 2015 and March 2017 who were followed-up for 3 years. They were divided into the myelin oligodendrocyte glycoprotein-seropositive (MOG-ON), aquaporin-4-seropositive (AQP4-ON), and double-seronegative (seronegative-ON) groups, and their clinical characteristics and imaging findings were evaluated and compared. Two-hundred-eighty patients (405 eyes) were included (MOG-ON: n = 57, 20.4%; AQP4-ON: n = 98, 35.0%; seronegative-ON: n = 125, 44.6%). The proportion of eyes with best-corrected visual acuity > 20/25 at the 3-year follow-up was similar between the MOG-ON and seronegative-ON groups; the proportion in both groups was higher than that in the AQP4-ON group (p < 0.001). Relapse rates were higher in the MOG-ON and AQP4-ON groups than in the seronegative-ON group (p < 0.001). Average retinal nerve fiber layer (RNFL) thickness at 3 years was similar between the MOG-ON and AQP4-ON groups (63.41 ± 13.39 and 59.40 ± 11.46 μm, p = 0.476) but both were thinner than the seronegative-ON group (74.06 ± 11.14 μm, p < 0.001). Macular ganglion cell-inner plexiform layer (GCIPL) revealed the same pattern. Despite RNFL and GCIPL thinning, the MOG-ON group's outcome was as favorable as that of the seronegative-ON group, whereas the AQP4-ON group showed unsatisfactory results.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34272440     DOI: 10.1038/s41598-021-93976-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  27 in total

1.  The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients.

Authors:  Jingzi ZhangBao; Lei Zhou; Xiaoyang Li; Tongjia Cai; Jiahong Lu; Chuanzhen Lu; Chongbo Zhao; Chao Quan
Journal:  J Neuroimmunol       Date:  2016-12-02       Impact factor: 3.478

Review 2.  Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.

Authors:  John J Chen; M Tariq Bhatti
Journal:  Curr Opin Neurol       Date:  2020-02       Impact factor: 5.710

3.  Clinical characteristics of optic neuritis in Hong Kong population: 10-year review.

Authors:  Bonnie Nga Kwan Choy; Alex Lap Ki Ng; Jimmy Shiu Ming Lai
Journal:  Int Ophthalmol       Date:  2017-03-13       Impact factor: 2.031

4.  Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.

Authors:  Huanfen Zhou; Shuo Zhao; Dongfang Yin; Xiaofei Chen; Quangang Xu; Tingjun Chen; Xiaoyan Li; Junqing Wang; Hongyang Li; Chunxia Peng; Dahe Lin; Shihui Wei
Journal:  J Neurol       Date:  2016-05-09       Impact factor: 4.849

5.  Clinical characteristics, therapeutic outcomes of isolated atypical optic neuritis in China.

Authors:  Chuntao Lai; Guohong Tian; Wu Liu; Wenbing Wei; Toshiyuki Takahashi; Xiaojun Zhang
Journal:  J Neurol Sci       Date:  2011-04-05       Impact factor: 3.181

6.  Clinical Characteristics of Pediatric Optic Neuritis With Myelin Oligodendrocyte Glycoprotein Seropositive: A Cohort Study.

Authors:  Qian Chen; Guixian Zhao; Yongheng Huang; Zhenxin Li; Xinghuai Sun; Ping Lu; Yan San; Min Wang; Guohong Tian
Journal:  Pediatr Neurol       Date:  2018-03-13       Impact factor: 3.372

Review 7.  Clinical and radiologic approach to 'typical' versus antibody-related optic neuritis.

Authors:  Marilou Caron-Cantin; Dean M Cestari; Elizabeth Fortin
Journal:  Curr Opin Ophthalmol       Date:  2019-11       Impact factor: 3.761

8.  Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China.

Authors:  Guixian Zhao; Qian Chen; Yongheng Huang; Zhenxin Li; Xinghuai Sun; Ping Lu; S Yan; Min Wang; Guohong Tian
Journal:  J Neurol       Date:  2017-11-03       Impact factor: 4.849

9.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

10.  Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity.

Authors:  Youming Long; Junyan Liang; Linzhan Wu; Shaopeng Lin; Cong Gao; Xiaohui Chen; Wei Qiu; Yu Yang; Xueping Zheng; Ning Yang; Min Gao; Yaotang Chen; Zhanhang Wang; Quanxi Su
Journal:  Front Neurol       Date:  2017-02-28       Impact factor: 4.003

View more
  2 in total

1.  Anti-inflammatory effect of miR-125a-5p on experimental optic neuritis by promoting the differentiation of Treg cells.

Authors:  Jia-Lin Zhan; Yan-Ling Huang; Qiao-Wen Liang; Xiao-Sheng Qu; Zi-Mei Dong; Yi Du; Wen-Jing Luo
Journal:  Neural Regen Res       Date:  2023-02       Impact factor: 6.058

Review 2.  What's new in neuromyelitis optica spectrum disorder treatment?

Authors:  Yi-Ching Chu; Tzu-Lun Huang
Journal:  Taiwan J Ophthalmol       Date:  2022-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.